The history of copyright's flagship drug presents a nuanced case for observers in the pharmaceutical sector. While initially a blockbuster success, creating billions, the exclusivity expiration and the subsequent flood of cheaper versions have significantly changed revenue. This poses questions about the ongoing sustainability of analogous drug … Read More